Umbrella Study of Sasanlimab Combined With Targeted Therapies in Participants With Non Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-12-20
Target enrollment:
Participant gender:
Summary
Phase 1b/Phase 2 open-label, multi-center, parallel group umbrella study.
Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted
therapy in each sub-study. The Phase1b part of each sub-study will evaluate the safety of the
combination and select the dose for the Phase 2 part. The Phase 2 part of each sub-study will
evaluate the anti-tumor activity of the combination.